A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)-Reference-Cited by-同舟云学术

A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)

Published:2011-12-16 Issue:16 Volume:118 Page:3968-3976
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bejanyan Nelli,Tiu Ramon V.,Raza Azra,Jankowska Ania,Kalaycio Matt,Advani Anjali,Chan Josephine,Saunthararajah Yogen,Mooney Lindsey,Maciejewski Jaroslaw P.,Sekeres Mikkael A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis;Dingli;Cancer.,2006

2. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status;Gangat;J Clin Oncol.,2011

3. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment);Passamonti;Blood.,2010

4. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients;Onida;Blood.,2002

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO;Current Hematologic Malignancy Reports;2019-11-27

2. Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular;Hematology, Transfusion and Cell Therapy;2019-07

3. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN);Clinical Lymphoma Myeloma and Leukemia;2019-01

4. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells;Cell Death & Disease;2018-09

5. Myelodysplastic Syndromes;Hematology;2018